Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Chief Financial Officer | May 15, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2035-05-15 | Direct | 543,785 |
Reported balance
After 2025-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-15 · Grant · Acquired 543,785 · Balance 543,785 F1: The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 16:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 543,785 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-073518 · ownership.xml · derivative · entry 1 Rees Heather · CIK 0001997454 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,785 Underlying: Common Stock · 543,785 shares Expires 2035-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 16:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 577,700 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-24-079560 · ownership.xml · derivative · entry 1 Rees Heather · CIK 0001997454 · SVP, Finance and Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,700 Underlying: Common Stock · 577,700 shares Expires 2034-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following June 27, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024, with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.